Introduction
A variety of medical and surgical strategies have been developed for the treatment of heart failure. However, heart failure still remains a major cause of morbidity and mortality in developed countries. Medical interventions for heart failure, which include adjustment of the preload, afterload and sometimes contractility, have limited efficacy in patients. Various types of surgery, including ventricular restoration, ventricular assist device implantation and transplantation, can be applied for only a limited number of patients. Therefore, a new 2 strategy to improve the cardiac function and inhibit cardiac remodeling needs to be established. A number of strategies to regenerate heart tissue have been devised to resolve the shortage of available transplantation organs, including the transplantation of cardiomyocytes or cardiomyogenic stem cells.
Several tissue-specific stem and progenitor cells, such as mesenchymal stem cells [1] and endothelial progenitor cells [2] , have been reported to possesses the potential to differentiate into cardiomyocytes. In addition, resident cardiac stem cells in the heart have also been reported to be able to differentiate into cardiomyocytes. In 2003, Beltrami et al. reported a population of resident cardiac progenitors with the expression of c-Kit is multipotent, differentiating into cardiomyocytes, smooth cells, and endothelial cells. [3] Cardiac side population cells with the potential for Hoechst dye exclusion and Sca-1+ cells have also been reported to have the potential to express cardiomyocyte-specific genes [4, 5] . Islet-1, a LIM homeodomain transcription factor, is expressed in the progenitor cells of the secondary heart field, and they maintain the ability to differentiate into functional cardiomyocytes both in vivo and in vitro [6] . However, whether these cells are present in the adult human heart remains to be elucidated. While these tissue stem or progenitor cells are an attractive source for stem cell-based cardiac regeneration, their self-renewal potential is limited, and in vitro cardiac differentiation is inefficient.
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Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are pluripotent cells that can be propagated indefinitely, and can differentiate into cell types from all three germ layers both in vitro and in vivo. The therapeutic effects of human ESC-and iPSC-derived progeny have been reported in animal models for several diseases [7] [8] [9] [10] [11] .
Establishment of iPS cells

1 Discovery of iPS cells
ESCs are derived from the inner cell mass of mammalian blastocysts, and mouse ESCs were first isolated in 1981 [12, 13] . The human ES cells derived from human blastocysts were first established by James Thomson et al. in 1998 [14] .
The iPS cells were first established in 2006 by Takahashi and Yamanaka [15] by the retrovirus-mediated transduction of four transcription factors (c-Myc, Oct3/4, SOX2, and Klf4) into mouse fibroblasts. These reprogrammed cells, which were selected by the expression of a beta-geo cassette (a fusion of the beta-galactosidase and neomycin resistance genes) driven by the mouse Fbx15 promoter, failed to contribute to adult chimeras. To obtain high-quality iPS cells, reprogrammed cells was selected for their expression of either Nanog or Oct3/4 expression, both of which are closely involved in pluripotency. These cells successfully contributed to adult chimeras, while also showing germline transmission [16] [17] [18] .
Human iPS cells were established in 2007, by the transduction of either the same set of transcription factors (c-Myc, Oct3/4, SOX2, Klf4) or another set of transcription factors (Oct3/4, SOX2, Nanog, Lin28) into human fibroblasts [19, 20] . These human iPS cells are similar to human ES cells in their morphology, gene expression, and the epigenetic status of pluripotent cell-specific genes, and they can differentiate into the cell types of the three germ layers in vitro and in vivo. Human iPS cells have been reported to be established from skin fibroblasts [19] [20] [21] , keratinocytes [22] , and mobilized CD34+ hematopoietic stem/progenitor cells [23] , and differentiated T cells from peripheral blood [24] [25] [26] . The human iPS cells provided us with a chance to develop new treatment modalities in the field of regenerative medicine, as well as being useful for in vitro disease modeling for drug screening [27, 28] .
2 Advancement of the methods in iPSC generation
iPS cells were initially derived from somatic cells by the retroviral or lentiviral transduction of transcription factors, and transgenes were randomly inserted into the genome of the hosts.
There are thus risks associated with the integrated transgenes, such as tumorgenicity. In fact, the chimeras and progenies derived from mouse iPSC have an increased incidence of 5 tumor formation primarily due to the reactivation of the c-Myc retrovirus [17] . To avoid these risks, iPS cells without transgenic insertion of c-Myc have been established, even with a low reprogramming efficiency [29] . These Myc -iPS cells achieve germline transmission and, Martinez-Fernandez et al. reported Myc -iPS cells to demonstrate robust cardiac differentiation properties [30, 31] . Recently Nakagawa et al reported that L-Myc, which has little transformation activity, instead of c-Myc, increased the reprogramming efficiency in human cells, and promoted germline transmission, but not tumor formation, in iPSC-derived chimeric mice [32] .
Several methods for delivering these transcription factors other than through retroviral or lentiviral transduction have also been devised. iPSCs can now be established by the transduction of the reprogramming factors with adenoviruses, sendaiviruses, plasmid vectors, and removable transposon systems [33] [34] [35] [36] [37] [38] . Moreover, mouse and human iPSCs could be established by the direct delivery of recombinant reprogramming proteins [39, 40] .
The repeated administration of synthetic modified messenger RNA has recently been reported to be able to reprogram the human somatic cells into iPS cells with a high efficiency [41] . (Figure 1 The most stringent criterion for mouse ES/iPS cells is their ability to generate germline-competent adult mouse chimeras, and thus undergo germline transmission.
Mouse iPS cells generated with OSK and Tbx3, a transcription factor related to the maintenance of pluripotency, have recently been reported to improve the germ-cell contribution to the gonads and germline transmission frequency [57] .
These in vitro and in vivo data clearly show that there are intrinsic qualitative differences between iPS cell lines and that the strict characterization of iPS cell lines is necessary.
Mouse ES cells are derived from the inner cell mass of blastocysts, and another type of pluripotent stem cells (epiblast stem cells) have recently been reported to have been generated [58, 59] Klf4, and Klf2, combined with LIF, GSK3β inhibitor, and MEK inhibitor, to make it possible to convert the ES cells into a more immature state with an active X-chromosome (XaXa) [62] .
These converted human ES cells have growth properties, gene expression profiles, and a signaling pathway-dependence similar to mouse ES cells. It was also reported that human ES cells with two active X chromosomes (XaXa) could be generated under hypoxic conditions (5% oxygen) [63] .
As noted above, there are variations in the characteristics of ES/ iPS cell lines, and the optimal method to best establish and maintain appropriate ES/iPS cell lines for ES/iPS cell technology applications still remains to be elucidated. Further studies are therefore required.
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Although the demonstration of germline-competent chimera formation and teratoma formation is very important to evaluate the pluripotency of stem cells, whether or not it should be applied for evaluating all iPS cells is controversial [64, 65] . For the purposes of either regenerative medicine or disease modeling, the optimal source cells do not have to be germline-competent or teratoma-competent, as long as they have the ability of self-renewal and differentiation into the necessary target cells [66] .
Generation of cardiomyocytes from pluripotent stem cells
Mouse and human ES/iPS cells can differentiate into various cell types, including cardiomyocytes, neuronal cells, and embryonic erythrocytes [67] [68] [69] [70] . However, the efficiency of cardiomyocyte differentiation is poor and the differentiated cells are a heterogeneous mixture of various types of cells. To improve the efficiency of cardiomyocyte differentiation, the directed differentiation of ES/iPS cells into cardiomyocytes was induced by the supplementation of signaling molecules, such as Activin A and BMP4 [8, 10] .
It has so far been reported that human cardiomyocytes could be induced from pluripotent stem cells by several methods (Figure 2) . Using an embryoid body formation assay, human ES/iPS cells can differentiate into beating cardiomyocytes in the presence of fetal bovine serum [71] [72] [73] , Under the serum-free conditions, with the supplementation of several cytokines, including Activin A and BMP4, the embryoid body can efficiently differentiate into cardiomyocytes [10] . Coculture with END-2 cells, visceral endoderm-like cells, also induce the cardiomyocytes from undifferentiated human ES cells [74, 75] . In a monolayer culture system of human ES/iPS cells, the directed differentiation of hES cells into cardiomyocytes can be achieved by sequential treatment with activin A and BMP4 [8] .
The identification and isolation of a cardiac precursor cell population is expected to provide a source of cells for tissue regeneration, while also providing valuable insight into cardiac reported a population of cardiovascular progenitor cells with low KDR and no c-Kit expression to be able to efficiently differentiate into cardiomyocytes in an in vitro differentiation system using human ES cells [10] .
A high-throughput screening system has also been utilized to identify small molecules that simulate the generation of cardiomyocytes from pluripotent stem cells. Using the high-throughput screening system, ascorbic acid was found to enhance the differentiation of ES cells into cardiomyocytes [81] .
Insight into the development of the heart can be further acquired through the observation of differentiation of ES cells into cardiomyocytes. Several studies have therefore focused on the development of cardiac tissue during mouse ES cell differentiation in vitro. [67, 82] . Developmental studies of human cardiomyocytes are now possible as a result of the recent availability of human ES/iPS cells. Moreover, ES/iPS cell-derived cardiomyocytes can also be used for the study of disease-specific cells, screening for new drugs, as well as for clinical application as a novel cell therapy.
Transplantation of cardiomyocytes derived from ES/ iPS cells
Human myocardium has recently been reported to form in infarcted rodent hearts using human ES cell-derived cardiomyocytes [8, 83, 84] . Nelson et al. reported that the intramyocardial delivery of mouse iPS cells also achieved the in situ regeneration of cardiac tissue, while also improving the post-ischemic cardiac function [85] . The poor survival of transplanted cells hinders the effective grafting of the working myocardium. The formation of an aggregation of derived cardiomyocytes or layered cell sheets of the cultured cardiomyocytes has been reported to improve the survival of grafted cardiac cells [86, 87] .
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As other types of transplanted cells, such as myoblasts or mononuclear bone marrow cells can be delivered by surgical procedures (epicardial approach) or cardiac catheter procedures (endocardial or intracoronary approach) [88, 89] , these delivery methods will be able to be applied to the transplantation of iPS cell-derived cardiac cells. However, several safety issues including teratoma formation still need to be addressed, before these technologies can be successfully used in clinical applications. 
